CytoDyn net loss widens to $42.7 million in FY26 - CYDY News | RalliesCytoDyn net loss widens to $42.7 million in FY26
C
CYDY• Cash position and trial updates
- Cash and cash equivalents ended at $11.9 million, little changed from a year earlier, while net cash used in operations increased to $17.3 million.
- Enrollment in the CLOVER Phase 2 trial topped 60 patients; a Natera collaboration will add ctDNA-guided analyses to trial samples and real-world data.
CytoDyn reports wider FY26 loss
- CytoDyn posted a net loss of $42.7 million, swinging from net income of $3.7 million a year earlier.
- Operating loss widened to $38.6 million as operating expenses climbed to $38.6 million, reflecting a $15.4 million legal settlement loss.
- Research and development expense rose 193% to $15.7 million, driven by higher clinical costs tied to the Phase 2 colorectal cancer CLOVER study.
META
•
